These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 23006947)
1. Autotransplantation for mantle cell lymphoma. Vose JM Cancer J; 2012; 18(5):427-31. PubMed ID: 23006947 [TBL] [Abstract][Full Text] [Related]
2. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma. William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781 [TBL] [Abstract][Full Text] [Related]
3. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064 [TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
5. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Geisler CH; Kolstad A; Laurell A; Jerkeman M; Räty R; Andersen NS; Pedersen LB; Eriksson M; Nordström M; Kimby E; Bentzen H; Kuittinen O; Lauritzsen GF; Nilsson-Ehle H; Ralfkiaer E; Ehinger M; Sundström C; Delabie J; Karjalainen-Lindsberg ML; Brown P; Elonen E; Br J Haematol; 2012 Aug; 158(3):355-62. PubMed ID: 22640180 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study. Decaudin D; Brousse N; Brice P; Haioun C; Bourhis JH; Morel P; Van Hoof A; Souleau B; Quesnel B; Gisselbrecht C Bone Marrow Transplant; 2000 Feb; 25(3):251-6. PubMed ID: 10673695 [TBL] [Abstract][Full Text] [Related]
7. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma. Joao C; Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Gastineau DA; Markovic SN Bone Marrow Transplant; 2006 May; 37(9):865-71. PubMed ID: 16532015 [TBL] [Abstract][Full Text] [Related]
8. Autologous transplantation and management of younger patients with mantle cell lymphoma. Geisler CH Best Pract Res Clin Haematol; 2012 Jun; 25(2):211-20. PubMed ID: 22687457 [TBL] [Abstract][Full Text] [Related]
9. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. Touzeau C; Leux C; Bouabdallah R; Roussel M; Delarue R; Bouabdallah K; Thieblemont C; Cacheux V; Cartron G; Compain L; Gyan E; Morschhauser F; Casasnovas O; Moles MP; Michallet AS; Gressin R; Damaj G; Rose C; Sirvent A; Hermine O; Mohty M; Milpied N; Le Gouill S Ann Hematol; 2014 Feb; 93(2):233-42. PubMed ID: 24563925 [TBL] [Abstract][Full Text] [Related]
10. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. Touzeau C; Leux C; Bouabdallah R; Roussel M; Delarue R; Bouabdallah K; Thieblemont C; Cacheux V; Cartron G; Compain L; Gyan E; Morschhauser F; Casasnovas O; Moles MP; Michallet AS; Gressin R; Damaj G; Rose C; Sirvent A; Hermine O; Mohty M; Milpied N; Le Gouill S Ann Hematol; 2014 Feb; 93(2):233-42. PubMed ID: 23949376 [TBL] [Abstract][Full Text] [Related]
11. [Current strategies in the treatment of advanced stage mantle cell lymphoma]. Lenz G; Dreyling M; Unterhalt M; Hiddemann W Dtsch Med Wochenschr; 2004 Nov; 129(45):2429-33. PubMed ID: 15529247 [TBL] [Abstract][Full Text] [Related]
12. Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission. Chakhachiro ZI; Saliba RM; Okoroji GJ; Korbling M; Alousi AM; Betul O; Anderlini P; Ciurea SO; Popat U; Champlin R; Samuels BI; Medeiros LJ; Bueso-Ramos C; Khouri IF Cancer; 2013 Sep; 119(18):3318-25. PubMed ID: 23775587 [TBL] [Abstract][Full Text] [Related]
13. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF; J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447 [TBL] [Abstract][Full Text] [Related]
14. Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Thieblemont C; Antal D; Lacotte-Thierry L; Delwail V; Espinouse D; Michallet AS; Traulle C; Bouafia-Sauvy F; Giraud C; Salles G; Guilhot F; Coiffier B Cancer; 2005 Oct; 104(7):1434-41. PubMed ID: 16104036 [TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. Mounier N; Gisselbrecht C; Brière J; Haioun C; Feugier P; Offner F; Recher C; Stamatoullas A; Morschhauser F; Macro M; Thieblemont C; Sonet A; Fabiani B; Reyes F; J Clin Oncol; 2004 Jul; 22(14):2826-34. PubMed ID: 15254050 [TBL] [Abstract][Full Text] [Related]
16. Autologous stem cell transplantation in first-line treatment of high-risk aggressive non-Hodgkin's lymphoma. Vranovsky A; Ladicka M; Lakota J Neoplasma; 2008; 55(2):107-12. PubMed ID: 18652043 [TBL] [Abstract][Full Text] [Related]
17. Long-term clinical and molecular remissions in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation. Metzner B; Müller TH; Gebauer W; Casper J; Kraemer D; Rosien B; Schumann-Binarsch S; Thole R; Köhne CH; Dreyling M; Hoster E; Pott C Ann Hematol; 2014 May; 93(5):803-10. PubMed ID: 24337447 [TBL] [Abstract][Full Text] [Related]
18. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557 [TBL] [Abstract][Full Text] [Related]
19. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study. Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276 [TBL] [Abstract][Full Text] [Related]